Clinical Trials

49 enrolled

Melanoma

NCT05926960 2026-03-09

PORTSIDE

Phase 2 Terminated

38 enrolled

Phase 4 Not yet recruiting

Melanoma, Skin Neoplasms

NCT07459543 2026-03-09

A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India

30 enrolled

Melanoma, Skin Neoplasms

NCT03036098 2026-03-06

CheckMate901

1,314 enrolled 23 charts 1 FDA

Urothelial Cancer

NCT05568095 2026-03-04

STAR-221

1,040 enrolled

Other solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06097728 2026-03-04

eVOLVE-Meso

Phase 3 Recruiting

825 enrolled

Mesothelioma, Malignant, Mesothelioma

NCT07221149 2026-03-04

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Phase 2/3 Recruiting

690 enrolled

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT07246863 2026-03-04

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

Other solid neoplasmThoracic

131 enrolled

Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT07293351 2026-03-04

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

234 enrolled

Carcinoma, Renal Cell

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

134 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT04336241 2026-02-27

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

BreastDermatologicGastrointestinalThoracic

36 enrolled

Uveal Melanoma, Breast Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasms

NCT04735978 2026-02-27

Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

123 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05907122 2026-02-27

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Phase 3 Completed

256 enrolled

Phase 1 Not yet recruiting

Melanoma

NCT07176975 2026-02-27

A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers

46 enrolled

Other solid neoplasm

Solid Tumors

NCT07276373 2026-02-27

Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

50 enrolled

Tumor-Agnostic

Neoplasms

NCT04895709 2026-02-25

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

BreastDermatologicGenitourinaryGynecologicHead & NeckThoracic

949 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05601752 2026-02-25

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

Phase 2 Active not recruiting

66 enrolled

Gynecologic

Ovarian Neoplasms

NCT07432295 2026-02-25

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

180 enrolled

Adenocarcinoma Of Esophagus, Neoplasm Metastasis, Stomach Neoplasms

NCT03400332 2026-02-24

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Phase 1/2 Completed

281 enrolled 44 charts

Melanoma, Neoplasms

NCT06946797 2026-02-24

CheckMate-1533

76 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07431281 2026-02-24

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Phase 3 Recruiting

2,130 enrolled

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT04039607 2026-02-19

CheckMate 9DW

732 enrolled 1 FDA

BreastGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Hepatocellular

NCT07334119 2026-02-19

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

Phase 1 Recruiting

60 enrolled

Adenocarcinoma Of Esophagus, Carcinoma, Ovarian Epithelial, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT03686124 2026-02-18

ACTengine

375 enrolled

DermatologicGynecologic

Uveal Melanoma, Melanoma, Neoplasms, Ovarian Neoplasms, Recurrence

NCT05267626 2026-02-18

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

159 enrolled

Diabetes Mellitus, Insulin-Dependent, 10, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Carcinoma, Merkel Cell

NCT06581406 2026-02-18

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Phase 2/3 Recruiting

280 enrolled

970 enrolled 15 charts 1 FDA

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT03143153 2026-02-17

CheckMate 648

Phase 3 Completed

Various Advanced Cancer

NCT03767348 2026-02-13

IGNYTE

Phase 2 Active not recruiting

340 enrolled

DermatologicThoracic

Turcot syndrome, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT07405164 2026-02-12

MK-6482-043

Phase 3 Not yet recruiting

450 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT04078295 2026-02-10

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

125 enrolled

Tumor-Agnostic

Neoplasms

NCT05533697 2026-02-06

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Phase 2/3 Not yet recruiting

361 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT07392892 2026-02-06

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

840 enrolled

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06880549 2026-02-05

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors

57 enrolled

Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence

NCT02393625 2026-02-03

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

57 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03661320 2026-02-03

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

855 enrolled

Urinary Bladder Neoplasms

NCT04835805 2026-02-03

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

65 enrolled

Melanoma

NCT06697197 2026-02-03

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

413 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT04187404 2026-01-30

Spencer

Phase 1/2 Terminated

70 enrolled 20 charts

CNSEndocrine

Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma

NCT03338790 2026-01-27

CheckMate 9KD

Phase 2 Completed

292 enrolled 21 charts

Other solid neoplasmThoracic

Prostatic Neoplasms

NCT05136677 2026-01-23

CheckMate 6DW

Phase 2 Completed

102 enrolled

Mesothelioma, Malignant

NCT06948448 2026-01-21

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

144 enrolled